CS 932
Latest Information Update: 19 Oct 2000
At a glance
- Originator Sankyo
- Class Neuroprotectants
- Mechanism of Action Muscarinic M1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 19 Oct 2000 Discontinued-Preclinical for CNS disorders in Japan (Unknown route)
- 14 Sep 1999 New profile
- 14 Sep 1999 Preclinical development for CNS disorders in Japan (Unknown route)